Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States

cT1-based pathway to assign suspected MASH patients to resmetirom and monitor response delivered the lowest per-patient costs in the VA: $7,022 (cT1) vs $7,268 (biopsy) vs $28,509 (VCTE), in the base-case and scenario analyses. Choose cT1: more efficient treatment allocation, better care, lower spend